Back to Search
Start Over
HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies
- Source :
- Journal of Clinical Oncology. 36:e16235-e16235
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- e16235Background: MVT-5873, a fully human IgG1 mAb, targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in PDAC and other GI and lung cancers, plays a role in tumor adhesion an...
- Subjects :
- 0301 basic medicine
Cancer Research
endocrine system diseases
medicine.drug_class
First line
Monoclonal antibody
Epitope
03 medical and health sciences
chemistry.chemical_compound
Pancreatic cancer
0502 economics and business
medicine
business.industry
05 social sciences
Adhesion
Sialyl-Lewis A
medicine.disease
digestive system diseases
Gemcitabine
030104 developmental biology
Oncology
chemistry
Cancer research
050211 marketing
CA19-9
business
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........91cf0be4bd870814431b3b9ebb105252
- Full Text :
- https://doi.org/10.1200/jco.2018.36.15_suppl.e16235